BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing ...
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced ...
-- Preliminary Results from the Phase 1a Trial Anticipated by Year-End -- “The initiation of the Phase 1a trial of STAR-0215 in healthy subjects is an important milestone for us, as it marks our ...
-- Shown Early Proof of Concept of STAR-0215’s Profile as a Long-Acting Plasma Kallikrein Inhibitor with Estimated Half-Life of Up to 110 Days -- -- Plans to Initiate ALPHA-STAR Phase 1b/2 Trial in ...
-- Results To-Date Support STAR-0215 Administration Once Every Three or Six Months for Robust Suppression of HAE Attacks -- BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results